Tanaka, Yoshiya
Kameda, Hideto
Saito, Kazuyoshi
Kaneko, Yuko
Tanaka, Eiichi
Yasuda, Shinsuke
Tamura, Naoto
Fujio, Keishi
Fujii, Takao
Kojima, Toshihisa
Anzai, Tatsuhiko
Hamada, Chikuma
Fujino, Yoshihisa
Matsuda, Shinya
Kohsaka, Hitoshi
Funding for this research was provided by:
Chugai Pharmaceutical
Article History
Received: 9 January 2018
Accepted: 18 June 2018
First Online: 20 July 2018
Ethics approval and consent to participate
: Ethical approval was obtained from each participating institution and all patients provided written informed consent for study participation.
: YT received research grants and/or speaking fees from Abbvie, Asahi Kasei Pharma, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Mitsubishi-Tanabe Pharma, MSD, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical, Teijin Pharma, UCB, and YL Biologics; HK received research grants and/or speaking fees from AbbVie, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe Pharma, Novartis, Pfizer, Sanofi, and Takeda Pharmaceutical; YK received research grants, consulting fees and/or speaking fees from AbbVie, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi-Sankyo, Eisai, Eli Lily, Janssen, Mitsubishi-Tanabe Pharma, Pfizer, Sanofi, and UCB; ET received consulting fees from AbbVie, Ayumi Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Nippon Kayaku, Pfizer, Takeda Pharmaceutical, and UCB; SY received research grants and/or speaking fees from Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Mitsubishi-Tanabe Pharma, and MSD; NT received research grants and/or speaking fees from Astellas Pharma, Asahi Kasei Pharma, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Mitsubishi-Tanabe Pharma, and Takeda Pharmaceutical; KF received research grants, consulting fees, royalties and/or speaking fees from Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi-Sankyo, Eisai, Integrated Development Associates, Janssen, Mitsubishi-Tanabe Pharma, Pfizer, Santen Pharmaceutical, Takeda Pharmaceutical, Taisho Toyama Pharmaceutical, and UCB; TF received research grants and/or speaking fees from AbbVie, Astellas Pharma, Daiichi Sankyo, Eisai, Mitsubishi-Tanabe Pharma, Ono Pharmaceutical, and Pfizer; TK received research grants and/or speaking fees from Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe Pharma, Nippon Kayaku, Novartis, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical; TA is an employee of EPS Corporation; CH received consulting fees from Chugai Pharmaceutical; and HK received research grants, consulting fees, and/or speaking fees from AbbVie, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Japan Blood Products Organization, Mitsubishi-Tanabe Pharma, MSD, Nippon Kayaku, Novartis, Ono Pharmaceutical, Pfizer, Takeda Pharmaceutical, and Teijin Pharma. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.